We report a case of an endobronchial obstructing lesion due to Rhizopus that proved fatal in a patient who had recently undergone umbilical cord blood transplant.
A 44-year-old man was admitted to the hospital to undergo umbilical cord blood transplant. Eight months prior to transplant he presented with pancytopenia and was diagnosed with M4 AML. His induction regimen included Ara-C and indarubicin. His course was complicated by vancomycin-resistant enterococcal bacteremia, which was treated with quinupristin/dalfopristin. A subsequent bone marrow aspirate demonstrated persistent blasts and further attempts at re-induction chemotherapy failed. The patient had no matching siblings and was deemed not to be a candi-date for autologous transplantation due to failure to mobilize an adequate number of CD34 + cells. Ultimately, the patient presented to our institution to undergo an unrelated umbilical cord blood transplant.
A pretransplant bone marrow aspirate revealed 10% blasts and a peripheral complete blood count showed a WBC of 1.7 with 41% neutrophils, 22% monocytes, a hematocrit of 27%, and a platelet count of 16 000. Five days before transplant his chest roentgenogram was normal. According to the transplant protocol, he received whole body radiation, cyclophosphamide, and antithymocyte immunoglobulin. One day post transplant he was started on daily antifungal prophylaxis with amphotericin B at 12 mg i.v. and 50 mg via inhalation. Five days post transplant he developed febrile neutropenia and his blood cultures grew vancomycin-resistant enterococci. He was treated with linezolid and defervesced. Despite aggressive G-CSF therapy the patient remained neutropenic.
Twenty-five days post transplant, a routine surveillance chest roentgenogram revealed a left upper lobe infiltrate (Figure 1a ). At the time the patient was asymptomatic having noted only a small decrease in his ability to exercise during physical therapy. He was not febrile and reported no cough. His examination was remarkable only for decreased breath sounds in the left upper lobe. He was pancytopenic with a WBC of Ͻ0.1 and had a platelet count of 25 000. A CT scan revealed complete opacification of the left upper lobe due to an endobronchial obstruction (Figure 1b Zygomycete infections are uncommon. When they do occur, it is almost always in an immunocompromised host. The two most common presentations are rhinocerebral and pulmonary. Rhinocerebral disease is most often seen in diabetic patients.
2,3 Early reviews and case series of pulmonary zygomycete infection suggest that 50-75% of reported cases occurred in patients with hematological malignancies. 4, 5 However, in a recent review of 87 cases of pulmonary zygomycete infection by Lee et al, 2 hematological malignancies made up only 28% of cases. Organ transplant and renal failure patients each accounted for 11-12%. Most cases, 49%, occurred in diabetics. 2 The vast majority of pulmonary zygomycete infections present with diffuse lung involvement. At lease one case of tracheal involvement leading to airway occlusion has been reported. 5 Primary involvement of the bronchial structures has only rarely been reported. Of the 17 cases of primary endobronchial involvement described in the literature, 14 (82%) were in diabetics. 1, 2, 6, 7 In our patient, the mean random serum glucose level was 125 mg/dl measured over a 29-day period prior to transplant and 178 mg/dl measured over a 23 day period post transplant. The elevated blood glucose is likely due to the routine use of solumedrol given to our patients starting at post-transplant day +5. To our knowledge, this case is the first to describe bronchial obstruction from a zygomycete infection in a bone marrow/cord blood transplant recipient.
Zygomycetes tend to invade the large vascular structures of the lung leading to thrombosis and infarction of the lung parenchyma. Hemoptysis invariably follows and is often fatal. In Bigby's review of 11 cases of endobronchial zygomycete infection, only nine were diagnosed antemortem. Five of these survived. Of the seven who did not survive, all died of massive hemoptysis. 1 The primary risks for zygomycete infection are acidosis and neutropenia. The mechanism by which acidosis promotes zygomycete growth may be related to iron. Iron is an essential element necessary for zygomycete growth. At physiologic pH, iron is tightly bound to transferrin making it unavailable to the fungus. As the pH decreases below 7.3, the ability of transferrin to bind iron decreases substantially. Unbound iron is then free to promote zygomycete growth. 8 Some authors have postulated that iron overload from multiple transfusions may promote infection in BMT recipients. However, the importance of iron overload in the pathogenesis of fungal infection is not clear given that patients with hemochromatosis do not appear to have higher rates of infection. 9 Diagnosis of zygomycete infection is difficult and is frequently made post-mortem. Sputum cultures are often negative. Tissue culture is problematic in that the mincing of the biopsy samples can cause the culture to be negative. The microbiology laboratory should be told in advance that zygomycete infection is suspected so that tissue samples may be processed without mincing. Although any positive culture should be considered highly suggestive of invasive infection in the appropriate host, definitive diagnosis requires that broad, non-septated hyphae be demonstrated invading tissue. 1 Treatment of endobronchial zygomycosis is primarily surgical. Given the high degree of vascular invasion and the resultant infarction, it is unlikely that amphotericin will be effectively delivered to the involved areas. Most of those successfully cured were able to undergo local resection followed by therapy with amphotericin B. The index of suspicion should be high in immunocompromised patients not responding to traditional therapy and intervention should be prompt.
